Continuing to expand its footprint in the oncogenic KRAS mutations space, Boehringer Ingelheim has entered into a licensing, development and commercialisation agreement with Lupin for LNP3794, a mitogen-activated protein kinase inhibitor. As part of the alliance, which has a total potential deal value of US$700 M, the two companies will look at combination therapies for KRAS-driven cancers by pairing LNP3794 with Boehringer’s own KRAS inhibitors for gastrointestinal and lung cancers.